NCT00093951已完成2 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimer's Disease
Saegis Pharmaceuticals101 个研究点 分布在 1 个国家目标入组 280 人开始时间: 2004年4月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 280
- 试验地点
- 101
研究概览
简要总结
The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
详细描述
SGS742 is a GABA(B) receptor antagonist. It is an orally active drug and possesses neurochemical and psychopharmacologic features that suggest it could improve memory and cognition in humans. The primary objective of the SGS742 clinical trial will be to determine the effect of SGS742 on memory and cognition in individuals diagnosed with mild to moderate Alzheimer's disease. The duration of the study is 3 months with 5 clinic visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 55 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •55 to 90 years of age
- •Diagnosed with mild to moderate Alzheimer's disease
- •Willing caregiver
- •In general good health
排除标准
- •Call 1-877-MY-MEMORY and ask to be referred to a study center located near you for entry criteria information.
- •Prohibited Meds:
- •Alzheimer's medications (Aricept, Exelon, Remydl, Nemenda)
研究者
研究点 (101)
Loading locations...
相似试验
已完成
2 期
Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)Alzheimer's DiseaseNCT00074529Merck Sharp & Dohme LLC512
已完成
2 期
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's DiseaseParkinson's Disease With Cognitive ImpairmentsNCT01211587Newron Pharmaceuticals SPA103
已完成
2 期
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.Alzheimers DiseaseDementiaAlzheimers Disease, FamilialNCT04623242Washington University School of Medicine194
已完成
2 期
Investigation of Memantine in the Treatment of Memory, Concentration or Attention ProblemsMemory DisorderRetention Disorder, CognitiveSubjective Cognitive ImpairmentMemory, Concentration or Attention ProblemsNCT01261741Merz Pharmaceuticals GmbH299
已完成
2 期
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease PatientsAlzheimer's DiseaseNCT01350362Noscira SA306